Form 4: United Therapeutics Director, Raymond Dwek, Acquires Stock Options

Raymond Dwek, a director at United Therapeutics, acquired 2,890 stock options on July 25, 2024, as part of an annual non-employee director award.

Summary

• On July 25, 2024, Raymond Dwek, a director of United Therapeutics Corp, acquired 2,890 stock options.
• The options were granted as part of an annual non-employee director award.
• The exercise price of these options is $336.37.
• The options vest on July 25, 2025, and expire on July 25, 2034.
• Following the transaction, Dwek directly owns 2,890 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options to a director is a routine event, but it can be interpreted as a sign of confidence in the company's future prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Director stock option grants are a common practice in publicly traded companies to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation plans.
• The specific number of options granted and the vesting schedule are typically determined by the company's compensation committee and are based on factors such as company performance, industry benchmarks, and individual contributions.

Stakeholder Impact

• The granting of stock options aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates